Measuring ligand efficacy at the mu-opioid receptor using a conformational biosensor

38Citations
Citations of this article
89Readers
Mendeley users who have this article in their library.

Abstract

The intrinsic efficacy of orthosteric ligands acting at G-protein-coupled receptors (GPCRs) reflects their ability to stabilize active receptor states (R*) and is a major determinant of their physiological effects. Here, we present a direct way to quantify the efficacy of ligands by measuring the binding of a R*-specific biosensor to purified receptor employing interferometry. As an example, we use the mu-opioid receptor (μ-OR), a prototypic class A GPCR, and its active state sensor, nanobody-39 (Nb39). We demonstrate that ligands vary in their ability to recruit Nb39 to μ-OR and describe methadone, loperamide, and PZM21 as ligands that support unique R* conformation(s) of μ-OR. We further show that positive allosteric modulators of μ-OR promote formation of R* in addition to enhancing promotion by orthosteric agonists. Finally, we demonstrate that the technique can be utilized with heterotrimeric G protein. The method is cell-free, signal transduction-independent and is generally applicable to GPCRs.

Cite

CITATION STYLE

APA

Livingston, K. E., Mahoney, J. P., Manglik, A., Sunahara, R. K., & Traynor, J. R. (2018). Measuring ligand efficacy at the mu-opioid receptor using a conformational biosensor. ELife, 7. https://doi.org/10.7554/eLife.32499

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free